Lantern Pharma (LTRN) Competitors $3.38 +0.01 (+0.30%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$3.38 0.00 (0.00%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. IKT, ALEC, EPRX, BDTX, KRRO, FTLF, NKTX, GLSI, TARA, and HURAShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Inhibikase Therapeutics (IKT), Alector (ALEC), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Korro Bio (KRRO), FitLife Brands (FTLF), Nkarta (NKTX), Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Its Competitors Inhibikase Therapeutics Alector Eupraxia Pharmaceuticals Black Diamond Therapeutics Korro Bio FitLife Brands Nkarta Greenwich LifeSciences Protara Therapeutics TuHURA Biosciences Lantern Pharma (NASDAQ:LTRN) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings. Does the MarketBeat Community favor LTRN or IKT? Lantern Pharma received 4 more outperform votes than Inhibikase Therapeutics when rated by MarketBeat users. Likewise, 76.47% of users gave Lantern Pharma an outperform vote while only 75.00% of users gave Inhibikase Therapeutics an outperform vote. CompanyUnderperformOutperformLantern PharmaOutperform Votes1376.47% Underperform Votes423.53% Inhibikase TherapeuticsOutperform Votes975.00% Underperform Votes325.00% Is LTRN or IKT more profitable? Lantern Pharma's return on equity of -56.91% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -56.91% -51.17% Inhibikase Therapeutics N/A -350.63%-201.82% Which has more volatility and risk, LTRN or IKT? Lantern Pharma has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Do institutionals & insiders have more ownership in LTRN or IKT? 28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer LTRN or IKT? In the previous week, Lantern Pharma and Lantern Pharma both had 1 articles in the media. Lantern Pharma's average media sentiment score of 1.89 beat Inhibikase Therapeutics' score of 1.73 indicating that Lantern Pharma is being referred to more favorably in the media. Company Overall Sentiment Lantern Pharma Very Positive Inhibikase Therapeutics Very Positive Which has higher earnings and valuation, LTRN or IKT? Lantern Pharma has higher earnings, but lower revenue than Inhibikase Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$15.96M-$1.84-1.84Inhibikase Therapeutics$260K560.42-$19.03M-$2.67-0.73 Do analysts recommend LTRN or IKT? Lantern Pharma presently has a consensus price target of $25.00, suggesting a potential upside of 639.64%. Inhibikase Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 231.63%. Given Lantern Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Lantern Pharma is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryLantern Pharma beats Inhibikase Therapeutics on 12 of the 14 factors compared between the two stocks. Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.45M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.908.7827.1420.06Price / SalesN/A255.64411.98157.10Price / CashN/A65.8538.2534.64Price / Book0.906.557.064.70Net Income-$15.96M$143.93M$3.23B$247.88M7 Day Performance-1.46%3.84%2.85%2.63%1 Month Performance-17.76%11.20%9.06%6.36%1 Year Performance-40.18%4.18%31.43%14.05% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma2.7268 of 5 stars$3.38+0.3%$25.00+639.6%-39.5%$36.45MN/A-1.9020Positive NewsIKTInhibikase Therapeutics1.5245 of 5 stars$1.95-0.5%$6.50+233.3%+22.9%$144.97M$260K-0.736Positive NewsALECAlector3.5174 of 5 stars$1.44-3.4%$4.00+177.8%-63.1%$143.99M$88.34M-0.85270Positive NewsShort Interest ↑Analyst RevisionEPRXEupraxia Pharmaceuticals2.2996 of 5 stars$3.97+0.8%$10.50+164.5%+38.9%$142.32MN/A-5.5129BDTXBlack Diamond Therapeutics3.4812 of 5 stars$2.48-3.9%$14.60+488.7%-61.1%$141.02M$70M-1.8690KRROKorro Bio3.5683 of 5 stars$14.85+1.8%$102.43+589.8%-64.8%$139.46M$4.82M-1.5770Positive NewsAnalyst RevisionGap UpFTLFFitLife Brands4.1971 of 5 stars$14.19-0.8%$20.50+44.5%-5.9%$133.26M$63.86M16.7920Positive NewsShort Interest ↑NKTXNkarta3.6657 of 5 stars$1.87-1.6%$14.67+684.3%-69.2%$132.69MN/A-0.99140Positive NewsAnalyst ForecastGLSIGreenwich LifeSciences2.2811 of 5 stars$9.45-2.2%$39.00+312.7%-32.1%$126.33MN/A-11.813Positive NewsTARAProtara Therapeutics2.4871 of 5 stars$3.27-2.1%$20.50+526.9%+20.1%$126.16MN/A-1.1630Analyst RevisionGap UpHURATuHURA BiosciencesN/A$2.88+2.5%$12.67+339.8%N/A$125.80MN/A0.00N/A Related Companies and Tools Related Companies IKT Alternatives ALEC Alternatives EPRX Alternatives BDTX Alternatives KRRO Alternatives FTLF Alternatives NKTX Alternatives GLSI Alternatives TARA Alternatives HURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LTRN Stock Free LTRN Stock Alerts